

Place patient identification
sticker here

**DOCTOR'S ORDER SHEET -
PHARMACY – KRYSTEXXA (pegloticase)**

Allergies: NKA

Height _____ Weight _____ kg

****UNAPPROVED ABBREVIATIONS****

QD, QOD, MgSO₄, MSO₄, MS, IU, U or -u, ug, Use of a Trailing Zero (X.0mg), Lack of a Leading Zero(Xmg)

DATE	TIME	ORDERS	NURSE SIGNATURE
		Assign to Outpatient status	
		PREMEDICATIONS:	
		0.9% sodium chloride (NS) IV at KVO	
		<input type="checkbox"/> No pre-medications necessary	
		<input type="checkbox"/> methylprednisolone sodium succinate injection _____ mg IV 30 mins prior to infusion	
		<input type="checkbox"/> diphenhydramine _____ mg IV x1 dose 30 mins prior to infusion	
		<input type="checkbox"/> diphenhydramine _____ mg PO x 1 dose 30 mins prior to infusion	
		<input type="checkbox"/> acetaminophen 650mg PO x 1 dose 30 mins prior to infusion	
		MEDICATION:	
		Krystexxa (pegloticase) in 0.9% NS 250ml IV infusion	
		Dose: 8mg	
		Route: Intravenous	
		Frequency: Every 2 weeks	
		Infusion Duration: 120 minutes	
		<i>If infusion-related reaction:</i>	
		1.) STOP infusion immediately;	
		2.) Increase 0.9% sodium chloride (NS) infusion to wide open rate;	
		3.) Administer PRN medications per infusion reaction medication ordered;	
		4.) Call Max Cart;	
		5.) Notify MD	
		INFUSION REACTION MEDICATIONS:	
		albuterol inhalation nebulizer solution 2.5mg/0.5ml (concentrated solution)	
		(Note: dilute with 2.5ml of NS for an albuterol 2.5mg/3ml dose)	
		<i>Dose: 2.5mg via nebulizer as needed for shortness of breath/wheezing</i>	
		diphenhydrAMINE injectable	
		<i>Dose: 25mg IV x 1 dose for urticaria, pruritus, shortness of breath. May repeat in 15 minutes if symptoms not resolved</i>	
		EPINEPHrine 1mg/ml (1:1000) injectable	
		<i>Dose: 0.3mg IM x1 dose as needed for anaphylaxis</i>	
		methylPREDNISolone sodium succinate 125mg injection	
		<i>Dose: 125mg IV x1 dose as needed for hypersensitivity</i>	
		NURSING ORDERS:	
		• Ensure G6PD levels have been checked prior to start of treatment. Pegloticase is contraindicated in patients with a G6PD deficiency.	
		• Ensure serum uric acid levels are drawn prior to treatment and consider discontinuing if levels increase to >6mg/dL, especially when 2 consecutive levels >6mg/dL are observed.	
		• Ensure patient is not taking any antihyperuricemic agents (allopurinol, febuxostat, probenecid) at any time during the course of Pegloticase treatment.	
		• Do not administer Pegloticase and notify provider if patient has a temperature >100°F, complains of symptoms of acute viral or bacterial illness, or if patient is taking antibiotics for current infection	
		• Monitor patient for signs/symptoms of hypersensitivity during infusion and for 60 mins post-infusion	
		• Discontinue IV line when therapy complete and patient stabilized	

REFERENCES: Krystexxa Prescribing Information

USE BALL POINT PEN FAX TO PHARMACY

Qualified Medical Provider signature

Date

Time

